Economic analyses of immune-checkpoint inhibitors to treat lung cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Malvezzi M, Bertuccio P, Rosso T, et al. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol. 2015;26:779–786.
   PubMed Web of Science ®Google Scholar
• Defossez G, Le Guyader-Perou S, Uhry Z et al. Estimations nationales de l’incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. Etude à partir des registres des cancers du réseau Francim. Résultats préliminaires. Saint-Maurice: Santé Publique France ed. 2019. 1 . 175–198.
   Google Scholar
• Vergnenègre A, Chouaïd C. Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC). Expert Rev Pharmacoecon Outcomes Res. 2018;18:519–528.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257–265.
   PubMed Web of Science ®Google Scholar
• Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33:2004–2012.
   PubMed Web of Science ®Google Scholar
• Helissey C, Champiat S, Soria JC. Immune checkpoint inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015;27:108–117.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135.
   PubMed Web of Science ®Google Scholar
• Assi HI, Kamphorst AO, Moukalled NM, et al. Immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer. 2018;124:248–261.
   PubMed Web of Science ®Google Scholar
• Prasad V, Wang R, Afifi SH, et al. The rising price of cancer drugs – a new old problem? JAMA Oncol. 2017;20:140–150.
   Google Scholar
• Hancock C, Green L, Lestingi T, et al. An attempt to quantitate “value” in medical oncologic therapy. Cureus. 2018;10. DOI:10.7759/cureus2810.
   PubMed Web of Science ®Google Scholar
• Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93:118–124.
   PubMed Web of Science ®Google Scholar
• Tartari F, Santoni M, Burattini L, et al. Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: recent insights and future challenges. Cancer Treat Rev. 2016;48:20–24.
   PubMed Web of Science ®Google Scholar
• Giuliani J, Bonetti A. Nivolumab in second-line treatment for advanced non-small-cell lung cancer with squamous-cell histology: a perspective based on pharmacologic costs. Clin Lung Cancer. 2017;18:1–3.
   PubMed Web of Science ®Google Scholar
• Aguiar P Jr, Giglio AD, Perry LA, et al. Cost-effectiveness and budget impact of lung cancer immunotherapy in South America: strategies to improve access. Immunotherapy. 2018;10:887–897.
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Gordon N, Davidescu M, et al. A pharmacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in firstline PD-L1-positive non-small cell lung cancer. J Natl Cancer Inst. 2017;109.
   PubMedGoogle Scholar
• Goeree R, Villeneuve J, Goeree J, et al. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes. J Med Econ. 2016;19:630–644.
   PubMed Web of Science ®Google Scholar
• Matter-Walstra K, Schwenkglenks M, Aebi S, et al. A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous NSCLC including PD-L1 testing. J Thorac Oncol. 2016;11:1846–1855.
   PubMed Web of Science ®Google Scholar
• Huang M, Lou Y, Pellissier J, et al. Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States. J Med Econ. 2017;20:140–150.
   PubMed Web of Science ®Google Scholar
• Shah S, Matthews SE, Sarasani S, et al. Cost-effectiveness of nivolumab vs. docetaxel as second-line treatment for advanced non-small cell lung cancer. In: Value Health. 2016;19:A732.
   Google Scholar
• Liu Q, Luo X, Peng L, et al. Nivolumab versus docetaxel for previously treated advanced non-small cell lung cancer in China: a cost-effectiveness analysis. Clin Drug Investig. 2020;40:129–137.
   PubMed Web of Science ®Google Scholar
• Ondhia U, Conter HJ, Owen S, et al. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC). J Med Econ. 2019;22:625–637.
   PubMed Web of Science ®Google Scholar
• Marine S, Stephane R, Nicolas P, et al. Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France. J Med Econ. 2020;23:464–473.
   PubMed Web of Science ®Google Scholar
• Bestvina CM, Vokes EE, Hoffman PC, et al. The cost and the benefit: front-line immunotherapy for non-small cell lung cancer. J Thorac Oncol. 2017;12:S1552.
   PubMedGoogle Scholar
• Huang M, Lou Y, Pellissier J, et al. Cost effectiveness of pembrolizumab vs. standard-of-care chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in the United States. Pharmacoeconomics. 2017;35:831–844.
   PubMed Web of Science ®Google Scholar
• Georgieva M, da Silveira Nogueira Lima JP, Aguiar P Jr, et al. Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer. Lung Cancer. 2018;124:248–254.
   PubMed Web of Science ®Google Scholar
• Hu X, Hay JW. First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: a cost-effectiveness analysis from the UK health care perspective. Lung Cancer. 2018;123:166–171.
   PubMed Web of Science ®Google Scholar
• She L, Hu H, Liao M, et al. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. Lung Cancer. 2019;138:88–94.
   PubMed Web of Science ®Google Scholar
• Liao W, Huang J, Hutton D, et al. Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China. J Med Econ. 2019;22:344–349.
   PubMed Web of Science ®Google Scholar
• Zhou K, Jiang C, Li Q. Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores. Lung Cancer. 2019;136:98–101.
   PubMed Web of Science ®Google Scholar
• Chouaïd C, Bensimon L, Clay E, et al. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Lung Cancer. 2019;127:44–52.
   PubMed Web of Science ®Google Scholar
• Insinga RP, Vanness DJ, Feliciano JL, et al. Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US. J Med Econ. 2018;21:1191–1205.
   PubMed Web of Science ®Google Scholar
• Huang M, Lopes GL, Insinga RP, et al. Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA. Immunotherapy. 2019;11:1463–1478.
   PubMed Web of Science ®Google Scholar
• Panje CM, Lupatsch JE, Barbier M, et al. A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland. Ann Oncol. 2020;31:501–506.
   PubMed Web of Science ®Google Scholar
• Witlox WJ, Van Asselt ADI, Wolff R, et al. Durvalumab for the treatment of locally advanced unresectable stage III non small-cell lung cancer: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2020;38:317–324.
   PubMed Web of Science ®Google Scholar
• Zhou K, Zhou J, Huang J, et al. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. Lung Cancer. 2019;130:1–4.
   PubMed Web of Science ®Google Scholar
• Cohen JT, Lin PJ, Sheinson DM, et al. Are national comprehensive cancer network evidence block affordability ratings representative of real-world costs? An evaluation of advanced non-small-cell lung cancer. J Oncol Pract. 2019;15:e948–e956.
   PubMed Web of Science ®Google Scholar
• Albaba H, Lim C, Leighl NB. Economic considerations in the use of novel targeted therapies for lung cancer: review of current literature. Pharmacoeconomics. 2017;35:1195–1209.
   PubMed Web of Science ®Google Scholar
• Verma V, Sprave T, Haque W, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018;6:128.
   PubMed Web of Science ®Google Scholar
• Keusters WR, de Weger VA, Hovels A, et al. Changing costs of metastatic non small cell lung cancer in the Netherlands. Lung Cancer. 2017;114:56–61.
   PubMed Web of Science ®Google Scholar
• Hess LM, Cui ZL, Wu Y, et al. Current and projected patient and insurer costs for the care of patients with non-small cell lung cancer in the United States through 2040. J Med Econ. 2017;20:850–862.
   PubMed Web of Science ®Google Scholar